New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.